Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsKaty REZVANI, Elizabeth J. SHPALL, Rafet BASAR, Sunil ACHARYA, Nadima UPRETY, David MARIN COSTA, Emily ENSLEY
Estimating the term…
Embodiments of the disclosure include methods and compositions related to targeting of HLA-G-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind HLA-G using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the HLA-G-targeting CARs also express particular a suicide gene and/or one or more particular cytokines.
A polynucleotide that encodes an anti-HLA-G chimeric antigen receptor (CAR), the CAR comprising (a) a KIR2DL4 extracellular domain or an anti-HLA-G antigen binding region of an HLA-G specific antibody, (b) a transmembrane domain, and (c) an intracellular domain that is not a KIR2DL4 intracellular domain.
As a composition of matter, a polynucleotide comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, or SEQ ID NO:80.
As a composition of matter, a polypeptide comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:
An antibody-drug conjugate, wherein the antibody portion is encoded by SEQ ID NO:55, SEQ ID NO:61, SEQ ID NO:67, or SEQ ID NO:73.
An antibody-drug conjugate, wherein the antibody portion comprises sequence comprising one or more of SEQ ID NOs:50-54, 56-60, 62-66, and 68-72.
A bi-specific or multi-specific antibody, comprising an HLA-G-specific antibody.
Dependencies are inferred from the claim text.